AnthonyB.El-KhoueiryMD

Oncology • Los Angeles, CA

Gastrointestinal Cancer

Associate Professor, Medicine, USC School of Medicine Phase I Program Director

Join to view full profile

Dr. El-Khoueiry is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. El-Khoueiry's full profile

Already have an account?

Office
1441 Eastlake Ave
Los Angeles, CA 90089
Phone+1 323-865-3900

Fax+1 323-860-0061
Is this information wrong?

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2003 - 2004
University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2002 - 2003
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2001 - 2002
University of Southern California/LAC+USC Medical CenterResidency, Internal Medicine, 1998 - 2001
Keck School of Medicine of the University of Southern CaliforniaClass of 1998

Certifications & Licensure

CA State Medical License 2000 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma Start of enrollment: 2005 Oct 01
Completed
Phase 2
Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib Start of enrollment: 2008 Mar 01
Completed
Phase 1
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer Start of enrollment: 2009 Mar 01
Completed
Phase 2
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy Start of enrollment: 2010 Dec 01
Terminated
Phase 2
Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors Start of enrollment: 2011 Mar 03
Completed
Phase 1
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors Start of enrollment: 2011 Feb 01
Terminated
Phase 1
Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Start of enrollment: 2012 Sep 06
Terminated
Phase 1
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Start of enrollment: 2012 Dec 01
Completed
Phase 2
Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors Start of enrollment: 2012 Sep 01
Suspended
Phase 1
Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction Start of enrollment: 2013 Aug 23
Terminated
Phase 1
Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors Start of enrollment: 2013 Nov 08
Completed
Phase 1
A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol) Start of enrollment: 2013 Nov 01
Completed
Phase 1
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Start of enrollment: 2014 Feb 01
Completed
Phase 2
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer Start of enrollment: 2014 Jan 01
Completed
Phase 1
Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment Start of enrollment: 2014 Apr 01
Completed
Phase 1
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma Start of enrollment: 2014 Jul 23
Terminated
Phase 2
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma Start of enrollment: 2015 Nov 01
Terminated
Phase 3
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 Start of enrollment: 2017 Feb 09
Completed
Phase 1, Phase 2
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Start of enrollment: 2018 Feb 07
Active, not recruiting
Phase 1
Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients Start of enrollment: 2018 Feb 20
Completed
Phase 1
FID-007 in Treating Participants With Advanced Solid Tumors Start of enrollment: 2018 May 25
Recruiting
Phase 1
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Start of enrollment: 2019 Feb 07
Active, not recruiting
Phase 3
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer Start of enrollment: 2021 Jul 28
Recruiting
A Study in Subjects With Advanced Solid Tumors Start of enrollment: 2019 Dec 10
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma.
Abou-Alfa, G., Geyer, S., Nixon, A., Innocenti, F., Shi, Q., Kumthekar, P., Jacobson, S., El Dika, I., Yaqubie, A., Lopez, J., Huang, B., Tang, Y., Wen, Y., Schwartz, ...> ;Cancer Research Communications. 2024 Mar 7
9 citations
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors.
Anthony B El-Khoueiry, James Clarke, Tobias Neff, Tim Crossman, Nirav Ratia, Chetan Rathi, Paul Noto, Aarti Tarkar, Ignacio Garrido-Laguna, Emiliano Calvo, Jordi Rodón...> ;British Journal of Cancer. 2023 Aug 1
1 citations
Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040).
Bruno Sangro, Thomas Yau, Anthony B El-Khoueiry, Masatoshi Kudo, Yun Shen, Marina Tschaika, Amit Roy, Yan Feng, Ling Gao, Urvi Aras> ;Clinical and Translational Science. 2023 Aug 1
2 citations
Profiling of Circulating Tumor Cells for Screening of Selective Inhibitors of Tumor-Initiating Stem-Like Cells.
Chia-Lin Chen, Juan Carlos Hernandez, Dinesh Babu Uthaya Kumar, Tatsuya Machida, Stanley M Tahara, Anthony El-Khoueiry, Meng Li, Vasu Punj, Suresh Kumar Swaminathan, A...> ;Advanced Science. 2023 May 1
4 citations
Adjuvant Chemoradiation in Patients with Lymph Node-Positive Biliary Tract Cancers: Secondary Analysis of a Single-Arm Clinical Trial (SWOG 0809).
Sepideh Gholami, Sarah Colby, David P Horowitz, Katherine A Guthrie, Edgar Ben-Josef, Anthony B El-Khoueiry, Charles D Blanke, Philip A Philip, Lisa A Kachnic, Syed A ...> ;Annals of Surgical Oncology. 2023 Mar 1
10 citations
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.
Jennifer L McQuade, Hans Hammers, Helena Furberg, Andreas Engert, Thierry André, George Blumenschein Jr, Nizar Tannir, Ari Baron, James Larkin, Anthony El-Khoueiry, Da...> ;JAMA Oncology. 2023 Jan 1
2 citations
ASO Visual Abstract: Adjuvant Chemoradiation in Patients with Lymph Node-Positive Biliary Tract Cancers - Secondary Analysis of a Single-Arm Clinical Trial (SWOG 0809).
Sepideh Gholami, Sarah Colby, David P Horowitz, Katherine A Guthrie, Edgar Ben-Josef, Anthony B El-Khoueiry, Charles D Blanke, Philip A Philip, Lisa A Kachnic, Syed A ...> ;Annals of Surgical Oncology. 2023 Mar 1
15 citations
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
Thomas Yau, Vittorina Zagonel, Armando Santoro, Mirelis Acosta-Rivera, Su Pin Choo, Ana Matilla, Aiwu Ruth He, Antonio Cubillo Gracian, Anthony B El-Khoueiry, Bruno Sa...> ;Journal of Clinical Oncology. 2023 Mar 20
31 citations
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and...
Funda Meric-Bernstam, Muralidhar Beeram, Erika Hamilton, Do-Youn Oh, Diana L Hanna, Yoon-Koo Kang, Elena Elimova, Jorge Chaves, Rachel Goodwin, Jeeyun Lee, Lisle Nabel...> ;The Lancet. Oncology. 2022 Dec 1
16 citations
DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.
Lian Zhang, Hong-Tao Li, Rachel Shereda, Qianjin Lu, Daniel J Weisenberger, Casey O'Connell, Keigo Machida, Woojin An, Heinz-Josef Lenz, Anthony El-Khoueiry, Peter A J...> ;Cancer Letters. 2022 Nov 1
15 citations
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Omid Hamid, Alberto A Chiappori, John A Thompson, Toshihiko Doi, Siwen Hu-Lieskovan, Ferry A L M Eskens, Willeke Ros, Adi Diab, Jean-Philippe Spano, Naiyer A Rizvi, Je...> ;Journal for Immunotherapy of Cancer. 2022 Oct 1
Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial.
Nick Freemantle, Patrick Mollon, Tim Meyer, Ann-Lii Cheng, Anthony B El-Khoueiry, Robin K Kelley, Ari D Baron, Fawzi Benzaghou, Milan Mangeshkar, Ghassan K Abou-Alfa> ;European Journal of Cancer. 2022 Jun 1
8 citations
Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective an...
Anthony B El-Khoueiry, Tim Meyer, Ann-Lii Cheng, Lorenza Rimassa, Suvajit Sen, Steven Milwee, Robin Kate Kelley, Ghassan K Abou-Alfa> ;BMC Cancer. 2022 Apr 9
100 citations
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.
Josep M Llovet, Roser Pinyol, Robin K Kelley, Anthony El-Khoueiry, Helen L Reeves, Xin Wei Wang, Gregory J Gores, Augusto Villanueva> ;Nature Cancer. 2022 Apr 1
407 citations
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Thomas Yau, Joong-Won Park, Richard S Finn, Ann-Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, James J Harding, Philippe Merle, Olivier Rosmorduc, Lucja...> ;The Lancet. Oncology. 2022 Jan 1
14 citations
Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma.
Lorenza Rimassa, Robin Kate Kelley, Tim Meyer, Baek-Yeol Ryoo, Philippe Merle, Joong-Won Park, Jean-Frederic Blanc, Ho Yeong Lim, Albert Tran, Yi-Wah Chan, Paul McAdam...> ;Liver Cancer. 2022 Jan 1
12 citations
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade.
Robin Kate Kelley, Rebecca A. Miksad, Irfan Cicin, Yen-Hsun Chen, Heinz-Josef Klümpen, Stefano Kim, Zhong-Zhe Lin, Jillian Youkstetter, S. Hazra, Suvajit Sen, Ann-Lii ...> ;British Journal of Cancer. 2021 Oct 7
31 citations
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers.
Adi Diab, Omid Hamid, John A. Thompson, Willeke Ros, Ferry A.L.M. Eskens, Toshihiko Doi, Siwen Hu-Lieskovan, Samuel J. Klempner, Bishu J Ganguly, Catherine Fleener, Xi...> ;Clinical Cancer Research. 2021 Oct 6
142 citations
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multice...
Moran, S. E., Milind Javle, Sameek Roychowdhury, Robin Kate Kelley, Saeed Sadeghi, Teresa Macarulla, Karl Heinz Weiss, Dirk Waldschmidt, Lipika Goyal, Ivan Borbath, An...> ;The Lancet. Gastroenterology & Hepatology. 2021 Oct 1
149 citations
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Andrew X. Zhu, Teresa Macarulla, Milind Javle, R. Kate Kelley, Sam J. Lubner, Jorge Adeva, James M. Cleary, Daniel V.T. Catenacci, Mitesh J. Borad, John Bridgewater, W...> ;JAMA Oncology. 2021 Nov 1
37 citations
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
Tim F. Greten, Ghassan K. Abou-Alfa, Ann-Lii Cheng, Austin G. Duffy, Anthony B. El-Khoueiry, Richard S. Finn, Peter R. Galle, Lipika Goyal, Aiwu Ruth He, Ahmed Kaseb, ...> ;Journal for Immunotherapy of Cancer. 2021 Sep 1
19 citations
IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.
Stephen P. Hack, Wendy Verret, S. Mulla, Bo Liu, Yulei Wang, Teresa Macarulla, Zhenggang Ren, Anthony B. El-Khoueiry, Andrew X. Zhu> ;Therapeutic Advances in Medical Oncology. 2021 Jul 31
8 citations
Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
Mehmet Akce, Anthony B. El-Khoueiry, Sarina Anne Piha-Paul, Emeline Bacque, Peng Pan, Zhi-Yi Zhang, Reginald Ewesuedo, Divya Gupta, Yongqiang Tang, Ashley Milton, Stef...> ;Cancer Chemotherapy and Pharmacology. 2021 Jul 29
11 citations
Etiology and Outcomes of Hepatocellular Carcinoma in an Ethnically Diverse Population: The Multiethnic Cohort.
Afsaneh Barzi, Kali Zhou, Songren Wang, Jennifer L. Dodge, Anthony B. El-Khoueiry, Veronica Wendy Setiawan> ;Cancers. 2021 Jul 12
24 citations
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies
Melissa Lynne Johnson, Anthony B. El-Khoueiry, Navid Hafez, Nehal Lakhani, Hirva Mamdani, Jordi Rodon, Rachel E. Sanborn, Javier Garcia-Corbacho, Valentina Boni, Mark ...> ;Clinical Cancer Research. 2021 Jun 3
Join now to see all

Lectures

Analysis of OX40 agonist antibody (PF-04518600) in patients with hepatocellular carcinoma.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Safety profile of INT230-6, a novel intratumoral (IT) formulation, during injections into a variety of refractory deep and superficial tumors with evidence of tumor re...
2019 ASCO Annual Meeting - 6/1/2019
A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Accelerated Approval of Nivolumab in HCC based on Phase I subgroup data. Continuous Evolution of a Phase I Trial Into An FDA Package
2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018
Join now to see all

Press Mentions

Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical OncologyMay 26th, 2023
Agenus (AGEN) Q1 2023 Earnings Call TranscriptMay 9th, 2023
Auransa Collaborates with USC Norris Comprehensive Cancer Center to Study AU409 in Liver Cancer Clinical TrialMarch 23rd, 2023
Join now to see all